Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.52 |
| ▸ | SLC2A3 | P11169 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.51 |
| ▸ | DHODH | Q02127 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16833392 | 0.90 | NT5E (0.54) | NT5ERXFP1MEN1KMT2ANPC1 | |
| SCHEMBL25735933 | 0.85 | RXFP1 (0.56) | RXFP1MEN1KMT2ANPC1PPARG | |
| SCHEMBL16832701 | 0.83 | ALDH1A1 (0.49) | NT5EMEN1KMT2ADHODHKDM4E | |
| SCHEMBL11669211 | 0.83 | DHODH (0.56) | NT5ERXFP1MEN1KMT2ASLC2A1 | |
| SCHEMBL16832709 | 0.82 | PTGES (0.58) | NT5EKMT2ADHODHKDM4EALDH1A1 | |
| SCHEMBL4214227 | 0.80 | NT5E (0.69) | NT5EMEN1KMT2ASLC2A1SLC2A3 | |
| SCHEMBL3041657 | 0.80 | KDM4E (0.57) | MEN1KMT2ANPC1DHODHKDM4E | |
| SCHEMBL16832506 | 0.79 | NT5E (0.39) | NT5ESLC2A1SLC2A3SLC2A2SLC2A4 | |
| SCHEMBL16832212 | 0.78 | DHODH (0.56) | NT5EDHODHKDM4EPOLBALDH1A1 | |
| SCHEMBL16833179 | 0.78 | EIF4A1 (0.40) | SLC2A1SLC2A3DHODHALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3172192-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172194-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| WO-2016202935-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016202935-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-106029647-A | Glucose transport inhibitors | 拜耳制药股份公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | NT5E 1658/4885RXFP1 2852/4885MEN1 1015/4885 |
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | NT5E 1658/4885RXFP1 2852/4885MEN1 1015/4885 |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | NT5E 1838/4885RXFP1 2782/4885MEN1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.